Beiersdorf Aktiengesellschaft Q1 Earnings Call Highlights

Beiersdorf Aktiengesellschaft (ETR:BEI) reported a challenging commencement to 2026 but said results were broadly successful enactment with expectations, supported by continued spot successful its Derma concern and improving sell-out trends contempt anemic first-quarter nett sales.

On the company’s Q1 2026 league call, CEO Vincent Warnery said absorption had anticipated a hard archetypal quarter, citing headwinds astatine La Prairie and Nivea, portion CFO Astrid Hermann highlighted overseas speech unit and respective region-specific disruptions. The institution confirmed its full-year 2026 guidance.

→ TSMC: Despite Post-Earnings Fall, Signs of AI Weakness are Scant

Warnery said radical integrated nett income declined 4.6% successful Q1 2026. The user concern fell 4.7% organically, portion Tesa posted an integrated nett income diminution of 4.3%.

Within consumer, show diverged by division:

• Derma grew 8.2% organically.

• Healthcare accrued 1.9% connected what Warnery described arsenic a “difficult anterior examination base.”

• Nivea declined 7% organically.

• La Prairie declined 14.9% organically.

→ $39 Trillion Debt Signal: 3 TIPS ETFs to Hedge Persistent Inflation

Hermann said user concern nett income were EUR 2.077 billion successful the quarter, and Tesa nett income were EUR 407 million. Group nett income totaled EUR 2.484 billion. She added that adverse overseas speech effects weighed connected nominal performance, with nominal income down 7.7% for some user and Tesa.

Warnery repeatedly pointed to Derma arsenic a cardinal maturation driver, saying the concern “again importantly outperformed the Derma market,” which helium characterized arsenic increasing astatine debased single-digit rates. He credited momentum to innovation and enlargement into “white spaces.”

→ Could These 3 New-to-Market Quantum Computing Firms Threaten D-Wave?

He highlighted ingredients including Epicelline and Thiamidol and said consumers are progressively seeking “science-backed, efficacious Derma products.”

By region, Warnery cited:

• North America: Derma’s largest region, with 7% integrated growth, driven by a “double-digit Aquaphor performance” and continued spot successful Eucerin look care.

• Brazil: Eucerin nett income “more than double[d]” successful Q1, with Warnery saying the marque is “close to taking the fig 3 position” 5 years aft being fig 15.

• China: continued “high double-digit growth,” which helium attributed to the rollout of Thiamidol.

Addressing a question aboriginal successful the call, Warnery besides said Eucerin showed “absolutely zero” cannibalization from Nivea Epicelline, noting that the products are typically sold successful antithetic channels (mass marketplace versus pharmacies). He added that Eucerin Epicelline is expanding with further SKUs specified arsenic time and nighttime products.